Regentis Biomaterials Ltd. (RGNT)
| Market Cap | 10.36M |
| Revenue (ttm) | n/a |
| Net Income | -13.69M |
| EPS | -24.16 |
| Shares Out | 5.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,636 |
| Open | 2.100 |
| Previous Close | 2.060 |
| Day's Range | 2.000 - 2.100 |
| 52-Week Range | 1.232 - 15.500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About RGNT
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Financial Performance
Financial StatementsNews
Regentis announces Japan Patent Office issued Notice of Allowance
Regentis Biomaterials (RGNT) announced that the Japan Patent Office has issued a Notice of Allowance for the Company’s patent application titled “Organic Solvent Free Compositions Comprising Protein-P...
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Patent expands intellectual property protection in one of the world's largest cartilage repair markets GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need f...
Regentis receives European regulatory approval for new GelrinC manufacturing
Regentis Biomaterials (RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process. The approval comes ...
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production GelrinC®,...
Regentis Biomaterials registers to sell 3.81M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.81M ordinary shares. The company is not selling any shares under…
Regentis Biomaterials prices $6.5M private placement at $3.50 per share
Regentis Biomaterials (RGNT) “announced that it has entered into definitive securities purchase agreements with accredited and institutional investors for the issuance and sale of ordinary shares (or ...
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solu...
Regentis Biomaterials Ltd trading resumes
10:38 EDT Regentis Biomaterials (RGNT) Ltd trading resumes
Regentis Biomaterials Ltd trading halted, volatility trading pause
10:25 EDT Regentis Biomaterials (RGNT) Ltd trading halted, volatility trading pause
Why Is Regentis Biomaterials Stock (RGNT) Up Today?
Regentis Biomaterials stock was up after the company withdrew an share offering.
Regentis Biomaterials Ltd trading resumes
12:25 EDT Regentis Biomaterials (RGNT) Ltd trading resumes
Regentis Biomaterials Ltd trading halted, news pending
11:41 EDT Regentis Biomaterials (RGNT) Ltd trading halted, news pending
Regentis Biomaterials to commence European surgeon training for GelrinC
Regentis Biomaterials (RGNT) announced that in the third quarter of 2026, the Company plans to commence its European surgeon training activities, as it advances preparations for the commercial rollout...
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European Union Regentis is growing its network of European Centers of ...
Regentis Biomaterials enters collaboration with Humanitas Research Hospital
Regentis Biomaterials (RGNT) announced a collaboration with Humanitas Research Hospital in Milan, Italy,. This collaboration is currently in the process of being formalized, is expected to support the...
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption Renowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellenc...
Regentis Biomaterials develops and patents solvent-free manufacturing process
Regentis Biomaterials (RGNT) has developed a new manufacturing process for its lead product, GelrinC, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful...
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year Proprietary process is already patented in several countries and is pending...
Regentis Biomaterials initiated with a Buy at ThinkEquity
ThinkEquity initiated coverage of Regentis Biomaterials (RGNT) with a Buy rating and $10 price target Regentis is a single-asset medtech company advancing GelrinC for focal knee cartilage defects, the...
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinC Already approved in Europe, GelrinC is expe...
Regentis Biomaterials appoints Galit Reke as CMO
Regentis Biomaterials (RGNT) announced the appointment of Dr. Galit Reske as Chief Medical Officer. Dr. Reske brings extensive experience in clinical development, regulatory strategy, and global clini...
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisition HE...
Regentis Biomaterials expands European clinical site network
Regentis Biomaterials (RGNT) announced the expansion of its European clinical site network into new countries, strengthening its infrastructure to support both ongoing clinical programs including its ...
Regentis Biomaterials appoints Ori Gon as CFO, CBO
Regentis Biomaterials (RGNT) announced the appointment of Ori Gon as CFO and CBO. Gon will lead the Company’s commercial and business development activities, as well as its financial strategy, plannin...
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S. Ori Gon brings substantial...